Original Source(s)
Related Content
Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount
“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce
October 12, 2026
-
3 min